No Data
Baiyang Pharmaceuticals (301015): Core business maintains steady growth, successful acquisition of pharmaceutical industry.
The company released its third quarter report for 2024, achieving revenue of 6.144 billion yuan in the first three quarters of 2024, a year-on-year increase of 2.65%; achieving a net income attributable to shareholders of the listed company of 0.641 billion yuan.
ZAP Surgical Secures $78M in Series E Funding Led by Baheal Medical
Baiyang Pharmaceuticals (301015.SZ): Subsidiary intends to participate in the subscription of Zap Medical System's issuance of E series preferred shares.
Geelong News November 8th | Baiyang Pharmaceutical (301015.SZ) announced that, in order to further deepen cooperation, promote resource integration and synergistic development, Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company")'s wholly-owned subsidiary Hebei Baiyang Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyang Chengda") and Baiyang Health Industry International Trade Co., Ltd. (hereinafter referred to as "Baiyang Health") intend to sign the "FIRST SERIES E PREFERENCE" agreement with Zap Medical System, Ltd. (hereinafter referred to as "the target company").
Baiyang Pharmaceutical (301015.SZ): signed a distribution agreement
Gelonghui, November 8th | Baiyang Pharmaceutical (301015.SZ) announced that, in order to expand the company's product layout in the high-end medical instruments field, the company and its wholly-owned subsidiary, Baiyang Health Industry International Trading Co., Ltd. (referred to as "Baiyang Health", together with the "Company" referred to as "Baiyang"), intend to sign the "INTERNATIONAL DISTRIBUTION AGREEMENT" with ZAP Surgical Systems, Inc. (referred to as "ZAP"), appointing Baiyang as the distributor of its "ZAP-
Express News | Baiyang Pharmaceutical: intends to become the exclusive dealer of the product 'ZAP-X System' and accessory 'Megavoltage Scintillation Detector'.
Express News | The self-developed nasopharyngeal cancer auxiliary diagnostic reagent kit by Tongxin Biosciences, a subsidiary of Baiyang Pharmaceuticals, has been approved for marketing.
No Data
No Data